Paratek Pharmaceuticals (PRTK) Trading Down 6.3%

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares traded down 6.3% during trading on Monday . The stock traded as low as $5.84 and last traded at $5.92. 535,111 shares were traded during mid-day trading, an increase of 77% from the average session volume of 301,682 shares. The stock had previously closed at $6.32.

Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, February 28th. Canaccord Genuity raised their price target on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, January 16th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, ValuEngine upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $23.25.

The company has a market cap of $202.63 million, a PE ratio of -1.66 and a beta of 1.52. The company has a debt-to-equity ratio of 4.81, a quick ratio of 14.41 and a current ratio of 14.41.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The firm had revenue of $17.02 million for the quarter, compared to analysts’ expectations of $16.50 million. Paratek Pharmaceuticals had a negative net margin of 656.41% and a negative return on equity of 149.09%. On average, analysts expect that Paratek Pharmaceuticals Inc will post -4.38 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of PRTK. JPMorgan Chase & Co. raised its stake in shares of Paratek Pharmaceuticals by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock valued at $3,271,000 after purchasing an additional 20,476 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Paratek Pharmaceuticals by 5.7% during the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock valued at $1,323,000 after purchasing an additional 7,332 shares during the period. BlackRock Inc. raised its stake in shares of Paratek Pharmaceuticals by 3.6% during the third quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock valued at $25,967,000 after purchasing an additional 93,764 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Paratek Pharmaceuticals during the third quarter valued at approximately $1,860,000. Finally, MetLife Investment Advisors LLC raised its stake in shares of Paratek Pharmaceuticals by 75.5% during the third quarter. MetLife Investment Advisors LLC now owns 28,473 shares of the specialty pharmaceutical company’s stock valued at $276,000 after purchasing an additional 12,251 shares during the period. Institutional investors own 74.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Paratek Pharmaceuticals (PRTK) Trading Down 6.3%” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2019/04/15/paratek-pharmaceuticals-prtk-trading-down-6-3.html.

Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: Federal Reserve

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.